RC-3095 (TFA)-5 mg

Description

RC-3095 TFA is a selective bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 TFA exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C58H80F3N15O11—-[1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63(10):2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486(1):35-41.–1217463-61-0–1220.34–98.12–O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O.OC(C(F)(F)F)=O–Inflammation/Immunology–H2O : 40 mg/mL (ultrasonic)–Bombesin Receptor—-GPCR/G Protein–Peptides